GDTC — CytoMed Therapeutics Balance Sheet
0.000.00%
- $26.75m
- $22.09m
- 44
- 27
- 74
- 46
Annual balance sheet for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.371 | 0.885 | 2.51 | 1.58 | 9 |
Net Total Receivables | 0 | 0.012 | 0.005 | 0.058 | 0.205 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.544 | 1.47 | 3.28 | 2.49 | 10.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.34 | 2.3 | 2.5 | 2.47 | 2.06 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 2.92 | 3.82 | 6.08 | 5.23 | 12.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.373 | 2.73 | 2.94 | 4.17 | 0.717 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Liabilities | 0.998 | 3.34 | 3.49 | 4.64 | 1.12 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1.92 | 0.476 | 2.59 | 0.587 | 11.2 |
Total Liabilities & Shareholders' Equity | 2.92 | 3.82 | 6.08 | 5.23 | 12.4 |
Total Common Shares Outstanding |